Practice patterns and impact of post-operative radiation therapy on overall survival after neoadjuvant chemotherapy for cN2 non-small cell lung cancer
In patients with locally-advanced non-small cell lung cancer (NSCLC) who undergo neoadjuvant chemotherapy followed by resection, the impact of post-operative radiation therapy (PORT) is unknown.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Z.D. Horne, S. Beriwal, S. Abel, A. Colonias, R.E. Wegner Source Type: research
Related Links:
In this report, we are adding an extra finding, in which we show that the levels of circulating NRP-1 were significantly increased in patients who received NAC and had a partial response. Assessing patients who underwent NAC indicated that the levels of NRP-1 measured post-NAC were significantly higher in younger patients and patients with either a low or a medium body mass index (BMI), as well as in patients who remained with larger tumor size and partial response. Previously, we showed that SNAI1 expression in the immune cells collected from the peripheral blood of breast cancer patients was significantly higher in patie...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Viacheslav Soyfer1* and Benjamin W. Corn2
1Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Israel
2Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel
Outcomes for patients with locally-advanced Non Small Cell Lung Cancer (NSCLC) remain poor. In the context of definitive (as opposed to neoadjuvant) treatment, radiation oncologists have traditionally embraced dose escalation as a means to improve control of the primary tumor as well as draining nodal regions for this clinical problem. Yet we wonder: is it optimal—or even rational—to treat the primary and the medi...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: : When used to treat LANSCLC in the neoadjuvant setting, both IMRT and 3DCRT produce comparable pathologic and clinical outcomes.
ADVANCES IN KNOWLEDGE: : This study validates the real-world effectiveness of IMRT compared to 3DCRT.
PMID: 30864828 [PubMed - as supplied by publisher]
Source: The British Journal of Radiology - Category: Radiology Authors: Appel S, Perelman M, Alezra D, Ben-Ayun M, Honig N, Dubinski S, Tsvang L, Kraitman J, Felder S, Haisraely O, Ofek E, Katzman T, Bar J, Urban D, Onn A, Chatterji S, Rabin Alezra T, Lieberman S, Marom EM, Golan N, Simansky D, Ben-Nun A, Symon Z, Lawrence YR Tags: Br J Radiol Source Type: research
Authors: Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M
Abstract
BACKGROUND: Programmed cell death-ligand 1 (PD-L1) is a checkpoint receptor that facilitates immune evasion by tumor cells, through interaction with programmed cell death-1 (PD-1), a receptor expressed by T-cells. Durvalumab is an anti-PD-L1 monoclonal antibody that blocks PD-L1 interaction with PD-1 on T-cells, countering the tumor's immune-evading tactics. Phase I/II studies demonstrated durable responses and manageable tolerability in heavily pre-treated patients with non-sma...
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
The treatment options for non-small cell lung cancer (NSCLC) are based mainly on cancer stage. Surgery is the historical gold standard for stages without mediastinal lymph node involvements (stages Ⅰ and Ⅱ), while a combination of chemotherapy and radiation therapy is used for patients with mediastinal lymph node metastasis (stage Ⅲ), although in some cases, a combination of surgery and neoadjuvant therapy is considered [1,2]. Therefore, the accurate staging of mediastinal lymph nodes in patients with NSCLC is of paramount importance.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Naohiro Taira, Eriko Atsumi, Saori Nakachi, Reika Takamatsu, Tomofumi Yohena, Hidenori Kawasaki, Tsutomu Kawabata, Naoki Yoshimi Source Type: research
Conclusions In our cohort, combined neoadjuvant chemotherapy and radiation therapy was associated with improved pathologic downstaging but showed increased perioperative mortality with no improvement in long-term overall survival. For stage IIIA patients with smaller tumors without local invasion, chemotherapy alone may be the preferred neoadjuvant treatment. Graphical abstract
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Neoadjuvant Chemoradiation Shows No Survival Advantage to Chemotherapy Alone in Stage IIIA Patients.
CONCLUSIONS: In our cohort, combined neoadjuvant chemotherapy and radiation therapy was associated with improved pathologic downstaging but showed increased perioperative mortality with no improvement in long-term overall survival. For stage IIIA patients with smaller tumors without local invasion, chemotherapy alone may be the preferred neoadjuvant treatment.
PMID: 29453000 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Krantz SB, Mitzman B, Lutfi W, Kuchta K, Wang CH, Howington JA, Kim KW Tags: Ann Thorac Surg Source Type: research
Abstract
The use of 4 cycles of cisplatin-based adjuvant chemotherapy is now the standard of care for patients with resected stage II and IIIA non-small cell lung cancer. Neoadjuvant chemotherapy lacks the same level of data as adjuvant treatment, but meta-analyses of this approach support its use. Selection of patients who are most likely to benefit from chemotherapy remain elusive. Ongoing adjuvant trials are exploring biomarkers, molecularly targeted agents, postoperative radiation therapy, and immunotherapy.
PMID: 27912832 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Chuang JC, Liang Y, Wakelee HA Tags: Hematol Oncol Clin North Am Source Type: research
Conclusions: This paper aims to alert for this rare and aggressive tumor, affecting mostly smoking male, which remains poorly explored. The better knowledge of PSC biology and molecular profile is critical for understanding the role of immunotherapy and targeted agents in this difficult to treat disease.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Cunha Machado, D. P., Campainha, S., Conde, S., Sanches, A., Barroso, A. Tags: 11.1 Lung Cancer Source Type: research
This study was designed to elucidate the predictive usefulness of the response evaluation criteria in solid tumors (RECIST), a volume response (VR; a> 50% reduction in the tumor volume) and the post-neoadjuvant therapy maximum standardized uptake value (post-SUVmax) in patients with non-small cell lung cancer (NSCLC) after neoadjuvant therapy. Between December 2006 and June 2012, 33 patients with clinical stage II and III NSCLC who underwent pulmonary resection following neoadjuvant therapy were enrolled. The relationships between the variables and a pathological complete response (pCR), the disease-free survival (DFS) ...
Source: Nagoya Journal of Medical Science - Category: Global & Universal Tags: Nagoya J Med Sci Source Type: research
